What Bliss Gvs Pharma does

Bliss GVS Pharma Ltd is an Indian pharmaceutical formulations company founded in 1984 and listed on the NSE (ticker BLISSGVS) and BSE, headquartered in Mumbai with manufacturing operations in Palghar, Maharashtra. The company develops, manufactures, and markets finished dosage forms spanning suppositories, pessaries, capsules, tablets, injectables, and syrups, with a particular focus on niche dosage forms that require specialized manufacturing capabilities not commonly found in commodity generics producers. Its manufacturing facilities are approved under US FDA, EU-GMP, and WHO-GMP regimes, with the Palghar plant's WHO GMP compliance confirmed by a WHO inspection closure report in June 2026.

The company supplies pharmaceutical formulations to regulated markets (US, Europe) and semi-regulated markets (Africa, Asia, Latin America), reaching healthcare providers and end-buyers through established pharmaceutical wholesale and distribution networks. Its revenue model is the sale of pharmaceutical products to distributors and institutional buyers, with pricing not publicly disclosed at the SKU level. Product breadth across multiple dosage forms serves as a hedge against single-product or single-therapeutic-area concentration, though end-customer concentration risk cannot be fully assessed given the absence of named buyer disclosures.

In May–June 2026, Anupam Rasayan India Ltd acquired a controlling 43.3–48.2% equity stake for approximately ₹1,369 crore at ₹299 per share, with a mandatory open offer filed through SBI Capital Markets Ltd for an additional 26% stake scheduled for July 2026; if fully subscribed, Anupam Rasayan would own up to 74.2% of Bliss GVS. The transaction positions Bliss GVS as the vehicle for Anupam Rasayan's entry into finished dosage formulations and signals forthcoming capital deployment for capacity, geographic, or product expansion, while Bliss GVS continues to operate as a standalone listed entity.

Name

Bliss Gvs Pharma

Legal name

Bliss GVS Pharma Ltd

Website

https://blissgvs.com

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Bliss GVS Pharma is an Indian pharmaceutical formulations manufacturer producing niche dosage forms including suppositories, injectables, tablets, capsules, pessaries, and syrups for distribution to regulated and semi-regulated global markets through pharmaceutical wholesale networks.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Oral Solid Dose (OSD) Generics (HLAIABAD)

Keywords

• Pharmaceutical formulations
• Niche dosage forms
• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Finished dosage formulations

Headquarters

HQ city

Andheri

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products Sales: Manufacturing and marketing of pharmaceutical formulations including suppositories, pessaries, injectables, capsules, tablets, and syrups sold to healthcare providers and distributors across regulated and semi-regulated markets

Distribution channels1 record

Core offering

Bliss GVS Pharma manufactures and markets pharmaceutical formulations in multiple dosage forms, including suppositories, pessaries, injectables, capsules, tablets, and syrups. The company operates WHO-GMP, US FDA, and EU-GMP approved manufacturing facilities, with its Palghar, Maharashtra facility confirmed compliant with WHO GMP standards. Its products are supplied to regulated markets (US, Europe) and semi-regulated markets (Africa, Asia, Latin America) through pharmaceutical distribution networks.

Product overview

Bliss GVS Pharma is an Indian pharmaceutical formulations company that manufactures and markets a range of dosage forms including suppositories, pessaries, capsules, tablets, injectables, and syrups. The company operates WHO-GMP, US FDA, and EU-GMP-approved manufacturing facilities and supplies to regulated markets in Africa, Asia, Latin America, Europe, and the United States. The product portfolio spans multiple therapeutic areas with a focus on niche dosage forms.

Differentiator

Problem solved

Functional benefit

Products and services

• Suppositories Pharmaceutical suppositories for drug delivery, manufactured at WHO-GMP, US FDA, and EU-GMP approved facilities. Targeted at pharmaceutical distributors and healthcare providers in regulated and semi-regulated markets.
• Pessaries Pharmaceutical pessaries for gynecological applications, including pelvic organ prolapse and stress urinary incontinence management, manufactured at the company's approved facilities.
• Capsules Pharmaceutical capsules manufactured at WHO-GMP, US FDA, and EU-GMP approved facilities for distribution in regulated and semi-regulated markets.
• Tablets Pharmaceutical tablets produced at WHO-GMP, US FDA, and EU-GMP certified manufacturing facilities for global regulated and semi-regulated markets.
• Injectables Sterile injectable pharmaceutical products manufactured at the company's facilities with international regulatory approvals (US FDA, WHO-GMP, EU-GMP) for global distribution.
• Syrups Pharmaceutical syrup formulations manufactured and marketed across regulated markets for global distribution through pharmaceutical wholesale networks.

Quantifiable outcome

• 29.8% YoY revenue growth to ₹257 crore in Q4 FY26
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ipca Laboratories: Indian generic pharma with US FDA and WHO-GMP approved plants exporting to regulated and semi-regulated markets. Comparable mid-scale formulations exporter with similar niche/specialty product orientation.
• Emcure Pharmaceuticals: Indian pharma with diversified dosage forms including injectables and OSD, exporting to regulated and semi-regulated markets globally. Comparable mid-cap Indian formulations exporter with multi-regulatory approvals.
• Ajanta Pharma: Indian generic formulations manufacturer with strong presence in Africa, Asia and other emerging markets plus US FDA-approved facilities. Directly comparable to Bliss GVS in geographic mix, regulatory profile, and specialty dosage-form orientation.
• Granules India: Indian pharma with US FDA-approved facilities focused on OSD generics and APIs with active pharmaceutical ingredient integration. Comparable vertically integrated Indian generics platform targeting regulated markets.
• Unichem Laboratories: Indian generic formulations manufacturer with US FDA-approved facilities serving US and emerging markets. Comparable mid-cap scale and regulatory profile to Bliss GVS.
• Glenmark Pharmaceuticals: Indian pharma with diversified generics portfolio across injectables, OSD and specialty dosage forms serving US, Europe and emerging markets. Comparable multi-dosage-form manufacturer with regulated-market exposure.
• Alembic Pharmaceuticals: Indian formulations company with US FDA-approved facilities supplying generics to regulated markets, plus API manufacturing. Comparable scale, regulatory profile, and emerging semi-regulated market presence.

Broad incumbents

• Zydus Lifesciences: Large Indian pharmaceutical company with US FDA, WHO-GMP and EU-GMP approved facilities across formulations, APIs and biologics. Broader portfolio and larger scale than Bliss GVS but overlapping dosage-form and regulatory profile.
• Cipla: Major Indian pharma with global presence across regulated and emerging markets, including complex generics and specialty dosage forms. Large-scale incumbent operating adjacent product categories and geographies.
• Lupin: One of India's largest generic pharma companies with US FDA-approved manufacturing and presence across injectables, OSD and specialty products. Larger scale incumbent overlapping with Bliss GVS in regulated-market generics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bliss Gvs Pharma